Investorideas.com newswire, breaking biotechnology and pharma news

Wednesday, April 26, 2017

Investor Ideas Podcast Corner; Dr. Sarath Malepati, Creator of the EZC Pak Talks about the Growing Antibiotic Resistance Crisis

Investor Ideas Podcast Corner; Dr. Sarath Malepati, Creator of the EZC Pak Talks about the Growing Antibiotic Resistance Crisis

Point Roberts, WA, Delta BC -April 26, 2017 – Investorideas.com, a global news source covering biotech and LOHAS,  releases a new Podcast interview with  Dr. Sarath Malepati, a leading expert and creator of the new over the counter supplement EZC Pak  https://www.ezcpak.com/ which is the first physician formulated immune support pack designed to reduce inappropriate antibiotic use. 


Dr. Sarath Malepati- creator of EZC Pak


To hear more Investorideas.com podcasts visit: http://www.investorideas.com/Audio/.

Investorideas.com podcasts are also available on iTunes, Google Play Music, Stitcher and Tunein.



About Investorideas.com - News that Inspires Big Ideas
Investorideas.com is a meeting place for global investors, featuring news, stock directories, video, podcasts, company profiles, interviews and more in leading sectors.
Sectors we cover in include tech, bitcoin and blockchain , biotech, mining, energy, renewable energy, water stocks, marijuana and hemp stocks, food and beverage (including organic and LOHAS, wine), defense and security including biometrics, Latin America, sports, entertainment, luxury brands and gaming.

The Investorideas.com content portfolio goes beyond the www.investorideas.com site to include 12 blogs on Blogger.com, 7 Artificial Intelligence (AI) websites on the Grid and the Waternewswire.com, all featuring Investorideas.com news and content.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers.

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Contact Investorideas.com
800-665-0411


BiotechIndustryStocks.com - investing ideas in biotechnology stocks, medical technology and life sciences



Like Biotech Stocks? View our Biotech Stocks Directory    Get News Alerts on Biotech Stocks

Aesthetic Medical Market News; RepliCel (OTCQB: $REPCF) (TSXV: $RP) Reports US Patent Issued for Novel Dermal Injection Technologies

Aesthetic Medical Market News; RepliCel (OTCQB: $REPCF) (TSXV: $RP) Reports US Patent Issued for Novel Dermal Injection Technologies

"We are confident RepliCel's extensive patent estate for its cell therapy and injection devices will provide our products with long-term market exclusivity," -Lee R. Buckler, CEO




VANCOUVER, BC - April 26, 2017 (Investorideas.com Newswire) Aesthetic Medical Market News alert ; RepliCel Life Sciences Inc. (OTCQB:REPCF) (TSXV:RP) (FRA:P6P2) ("RepliCel" or the "Company"), a clinical stage regenerative medicine company developing cell therapies for aesthetic and orthopedic conditions, today announced the granting of a key patent in the United States (U.S. Patent No. 9,616,182) covering significant components of the Company's novel, multi-needle dermal injection device.



Tuesday, April 25, 2017

Four Stocks Competing in the Medical Aesthetic Market; (NYSE: $AGN), (OTCQB: $REPCF) (TSXV: $RP), (NASDAQ: $HOLX), (ZLTQ)

Four Stocks Competing in the Medical Aesthetic Market; (NYSE: $AGN), (OTCQB: $REPCF) (TSXV: $RP), (NASDAQ: $HOLX), (ZLTQ)


Point Roberts, WA, -April 25, 2017 – Investorideas.com, a global news source covering biotech and medical technology, issues a sector close–up on publicly traded companies competing in the rapidly growing medical aesthetic market.

Company news from Allergan (NYSE: AGN), RepliCel (OTCQB:REPCF) (TSXV:RP), Hologic (NASDAQ: HOLX) and ZELTIQ Aesthetics, Inc. (NASDAQ:  $ZLTQ) showcases recent developments in the sector.


Breaking RepliCel (OTCQB: $REPCF; TSX: $RP.V) @RepliCel News; US Patent Issued to for its Novel Dermal Injection Technologies

Breaking RepliCel (OTCQB: $REPCF; TSX: $RP.V) @RepliCel News; US Patent Issued to for its Novel Dermal Injection Technologies

With exclusive U.S. rights to RCI-02 patents, RepliCel edges its nearest-term commercial asset closer to launch in large aesthetic market



VANCOUVER, BC – April 25, 2017 - (Investorideas.com Newswire) RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV:RP) (FRA:P6P2) (“RepliCel” or the “Company”), a clinical stage regenerative medicine company developing cell therapies for aesthetic and orthopedic conditions, today announced the granting of a key patent in the United States (U.S. Patent No. 9,616,182) covering significant components of the Company’s novel, multi-needle dermal injection device. 








Read this release in full at http://www.investorideas.com/news/2017/biotech/04251REPCF.asp

Friday, April 21, 2017

Biotech, GPS, & Tech Stocks Added to Investorideas.com


 Biotech, GPS, & Tech Stocks Added to Investorideas.com



Point Roberts, WA, Delta BC – April 21, 2017 – Investorideas.com, a global news source and investor resource covering actively traded sectors announces this week’s additions to its investor membership, including global stock directories in GPS, technology and biotech.

Investorideas.com tracks companies in high profile trading sectors and makes ongoing additions to its stock directories for each sector.  Listing for the stock directories include companies on the TSX, OTC, NYSE, NASDAQ and global stock exchanges.

The newest GPS stocks include DSG Global Inc. (OTC:DSGT) a provider of patented electronic tracking systems and fleet management solutions to golf courses that is now expanding into Commercial Fleet Management, and Agricultural applications and Ultrack Systems Inc. (OTC:MJLB), a GPS tracking solution provider for service driven industries.

Also new this week in tech is the Indonesian-based, digital payment company KinerjaPay Corp (OTC: KPAY), who enable consumers to "Pay, Play and Buy" through secure web portal and mobile applications.

The latest additions in biotech include a specialty biotechnology company that has a proprietary transdermal delivery system platform used to deliver pharmaceutical and natural molecules in a targeted specific manner (this company has also recently crossed over into the medical marijuana field) and Cellular Biomedicine Group, Inc. (NASDAQ: CBMG), a stem cell biotech company developing proprietary cell therapies for the treatment of cancer and degenerative diseases.
   
New Technology Companies Added to Investorideas directory:
DSG Global Inc. (OTC:DSGT) provides patented electronic tracking systems and fleet management solutions to golf courses that allow for remote management of the course's fleet of golf carts, turf equipment and utility vehicles. Their clients use DSGT's unique technology to significantly reduce operational costs, increase safety, and enhance customer satisfaction. DSGT has grown to become a leader in the category of Fleet Management in the golf industry, with their technology installed in over 15,000 vehicles on more than 250 courses worldwide. DSGT is now aggressively branching into several new streams of revenue, through programmatic advertising, licensing and distribution. DSGT is also expanding into Commercial Fleet Management, and Agricultural applications.

Ultrack Systems Inc. (OTC:MJLB) is a provider of GPS tracking solutions. We develop, implement and distribute electronic monitoring and tracking systems for companies in leasing, transportation, construction, disposal and many other service driven industries. Our platform includes live tracking, reports and alerts on a web-based platform. Our mission is to provide the best fleet tracking, reporting systems and our commitment to service.

KinerjaPay Corp ( OTC: KPAY) enables consumers to "Pay, Play and Buy" through its secure web portal and mobile applications. Based in Indonesia, the Company provides easy and convenient payment solution while shopping online at its marketplace platform. With its current omni-channel platform, users can perform various payment services such as credit card bill payment, utility, phone bill, healthcare insurance and direct transfer to anyone at their convenience. KinerjaPay is also planning to launch other eCommerce verticals such as travel market, delivery services, and online gaming in the near future

New Biotech Companies Added:
Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) develops proprietary cell therapies for the treatment of cancer and degenerative diseases. We conduct immuno-oncology and stem cell clinical trials in China using products from our integrated GMP laboratory. Our GMP facilities in China, consisting of twelve independent cell production lines, are designed and managed according to both China and U.S. GMP standards.  CBMG recently commenced two Phase I human clinical trials in China using CAR-T to treat relapsed/refractory CD19+ B-cell Acute Lymphoblastic Leukemia (ALL) and Refractory Diffuse Large B-cell Lymphoma (DLBCL) as well as an ongoing Phase I trial in China for AlloJoinTM (CBMG`s "Off-the-Shelf" Allogeneic Human Adipose-derived Mesenchymal Stem Cell) for the treatment of Knee Osteoarthritis (KOA). CBMG was also recently awarded $2.29 million from the California Institute for Regenerative Medicine (CIRM) to support pre-clinical studies of AlloJoinTM for Knee Osteoarthritis in the United States.

Delivra Corp. (TSX:DVA.V) is a specialty biotechnology company that has a proprietary transdermal delivery system platform that can shuttle pharmaceutical and natural molecules, through the skin, in a targeted specific manner. Delivra manufactures and sells a growing line of natural topical creams with the proprietary transdermal delivery system platform under the LivRelief™ brand, for conditions such as joint and muscle pain, nerve pain, varicose veins, wound healing, and under the LivSport™ brand for sports performance. LivRelief™ products are available in pharmacies, grocery chains, and independent health food stores across Canada, and on-line at www.livrelief.com. LivRelief™ pain and nerve pain products are also available in the United States on Amazon and at www.livrelief.com/us. In parallel with its consumer products business, Delivra also has a mandate to license its patent-pending proprietary transdermal delivery technology platform to pharmaceutical companies globally, for the repurposing of pharmaceutical molecules transdermally to treat a broad range of conditions, along with licensing its over-the-counter products globally. Delivra is headquartered in Burlington, Ontario and has a research and development laboratory in Charlottetown, PEI.


Investorideas.com global stock directories are part of the membership program on the site, accessed either by login and password or available in PDF format.  The directories include stocks trading on the TSX, OTC, NASDAQ, NYSE and other recognized global stock exchanges, giving retail investors a wide variety of stocks to review. http://www.investorideas.com/membership/

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

About Investorideas.com - News that Inspires Big Ideas
Investorideas.com is a meeting place for global investors, featuring news, stock directories, video, podcasts, company profiles, interviews and more in leading sectors.

Sectors we cover include tech, bitcoin and blockchain, biotech, mining, energy, renewable energy, water stocks, marijuana and hemp stocks, food and beverage (including organic and LOHAS, wine), defense and security (including biometrics), Latin America, sports, entertainment, luxury brands and gaming.

The Investorideas.com content portfolio goes beyond the www.investorideas.com site to include 12 blogs on Blogger.com, 7 Artificial Intelligence (AI) websites on the Grid and the Waternewswire.com, all featuring Investorideas.com news and content.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Investor Ideas Directories for global investors:
From water stocks to gold and mining stocks, renewable energy, nanotech, defense, technology, biotech and more – use our stock directories and access them online 24/7 with login as a member to find your next big idea!

Services for Publicly traded companies: http://www.investorideas.com/Investors/Services.asp

Investorideas.com CSE service provider directory listing: http://thecse.com/en/services/services-for-listed-companies


Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution,social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.  Global investors must adhere to regulations of each country.

Contact Investorideas.com
800-665-0411















Thursday, April 13, 2017

New #Biotech #Stocks Added to #Investorideas Directory – $VLRX, $XBIO


New #Biotech #Stocks Added to #Investorideas Directory – $VLRX, $XBIO



Point Roberts, WA, Delta BC – April 13, 2017 – Investorideas.com, a global news source and investor resource covering actively traded sectors announces this week’s additions to its investor membership, including global stock directories in energy, mining, biotech, sports and automotive.

Investorideas.com tracks companies in high profile trading sectors and makes ongoing additions to its stock directories for each sector.  Listing for the stock directories include companies on the TSX, OTC, NYSE, NASDAQ and global stock exchanges.

The newest additions to the energy stocks directories are all TSX and TSX Venture listed companies engaged in oil and/or oil and gas exploration.  These companies operate in North America, Oceania, Africa, Europe and New Zealand.

The latest additions to the mining sector are TSX and ASX (Australia) listed companies operating in the exploration and production of zinc, gold and potash with operations in North, South and Central America and Ireland and include one company crossing over into the agriculture sector - Aguia Resources Limited (ASX:AGR.AX), a fertilizer company that is mining, exploring and developing  phosphate and potash projects in Brazil.

Biotech additions are both Nasdaq-listed and include a company working with treatment for diabetes as well as a company developing oncology therapeutics.

Finally, the sports sector has been updated with Netshoes (Cayman) Limited (NYSE: NETS), a Latin American sporting goods retailer and Sport Endurance, Inc. (OTCQB:SENZ), a manufacturer of nutritional supplement products. The automotive sector has added the TSX-Listed Xpel Technologies (TSX: DAP-U.V) a leading supplier of automotive paint, headlamp and window protection films.
   
New Energy Companies Added to Investorideas directory:
Dundee Energy Limited (TSX:DEN.TO) is a Canadian-based oil and natural gas company with a mandate to create long-term value for its shareholders through the exploration, development, production and marketing of oil and natural gas, and through other high impact energy projects. Dundee Energy holds interests, both directly and indirectly, in the largest accumulation of producing oil and gas assets in Ontario and, through a preferred share investment, in certain exploration and evaluation programs for oil and natural gas offshore Tunisia.

Eagle Energy Inc. (TSX:EGL.TO) owns stable, primarily oil producing properties with development and exploitation potential in Canada and the United States. Eagle operates all four of its major assets.

East West Petroleum (TSX:EW.V) is a company established in 2010 to invest in international oil & gas opportunities. East West has built a diverse portfolio of attractive exploration assets covering a gross area of over one million acres. The Company has its primary focus on two key areas: New Zealand, where it has established production and cash flow and is evaluating a low risk exploration play, and Romania where it is fully carried on a seismic surveying and 12 well exploration program. In New Zealand, East West holds an interest in three exploration permits near to existing commercial production in the Taranaki Basin, operated by TAG Oil Ltd. The Company also has interests in four exploration concessions covering 1,000,000 acres in the prolific Pannonian Basin of western Romania with Naftna Industrija Srbije ("NIS").

Energulf Resources Inc. (TSX:ENG.V) is a publicly traded international oil and gas exploration company focused on maximizing shareholder value by targeting high impact opportunities that present explosive growth potential for shareholders. EnerGulf Resources Inc. is a Toronto, Canada based oil and gas exploration company. It also has offices in Kinshasa, Democratic Republic of Congo. EnerGulf’s subsidiaries are EnerGulf Corporation, EnerGulf Africa Ltd., EnerGulf Namibia Ltd., EnerGulf DRC, Ltd. and EnerGulf Congo, SARL.

Esrey Energy Ltd. (TSX:EEL.V) (formerly LNG Energy Ltd.) is a Canadian petroleum exploration and development company focused on developing oil and gas reserves in Papua New Guinea and Bulgaria.

Forent Energy Ltd. (TSX:FEN.V) is a Calgary-based junior oil and natural gas producer focused on near-term growth through asset acquisitions, infill development drilling of oil producing properties in Southern Alberta and exploration drilling for high impact, multi-zone oil and gas potential at Montgomery, Alberta. Forent is well positioned for growth as it has an experienced, technically based management team, strong board of directors, sustainable production base and manageable debt.

New Mining Companies Added:
Adventus Zinc Corporation (TSX:ADZN.V) is a newly formed company focused on zinc exploration in Ireland and Eastern Canada, as well as pursuing the acquisition of advanced zinc projects. Its major shareholders are experienced and respected investors in the mining business, providing significant financial and technical support.

Aguia Resources Limited (ASX:AGR.AX) a fertilizer company, mines, explores, and develops phosphate and potash projects in Brazil. Its flagship Rio Grande phosphate assets include the Três Estradas, Joca Tavares, Porteira carbonatite, and Cerro Preto deposits, which cover an area of approximately 78,150 hectares located in the state of Rio Grande do Sul in southern Brazil..
                             
Alicanto Mining Corp. (ASX:AQI.AX) is an ASX listed mineral exploration Company focused on the exploration and development of a portfolio of gold projects in the prospective geological province of the Guiana Shield in South America. In addition to the exploration of its current Guyanese projects, the Company is continuously evaluating additional projects in both Guyana and overseas for potential joint venture or acquisition.

Anconia Resources Corp. (TSX:ARA.V) is a base and precious metals exploration and development company, which is focused on providing shareholder value through the advancement of its properties in its portfolio. Anconia is undertaking comprehensive exploration programs to determine the potential of its current projects.

Ascendant Resources Inc. (TSX:ASND.V) (formerly known as Morumbi Resources Inc.) is a mining issuer focused on its flagship operating asset, the producing El Mochito zinc, silver and lead mine in west-central Honduras in which the Company has a 100% interest. El Mochito has been in almost continuous production since 1948. More broadly, the Company evaluates producing and advanced development stage mineral resource acquisition opportunities in North, South and Central America, on an ongoing basis.

New Biotech Companies Added:
Valeritas Holdings, Inc. (NasdaqCM:VLRX) is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies. Valeritas’ flagship product, V-Go® Wearable Insulin Delivery device, is a simple, wearable, basal-bolus insulin delivery device for patients with type 2 diabetes that enables patients to administer a continuous preset basal rate of insulin over 24 hours. It also provides discreet on-demand bolus dosing at mealtimes.  It is the only basal-bolus insulin delivery device on the market today specifically designed keeping in mind the needs of type 2 diabetes patients. Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D functions in Shrewsbury, Massachusetts.

Xenetic Biosciences Inc. (NasdaqCM: XBIO) is a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics. Xenetic's proprietary drug development platforms include PolyXen™, which enables next generation biologic drugs by improving their half-life and other pharmacological properties. Xenetic's lead investigational product candidates include oncology therapeutic XBIO-101 (sodium cridanimod) for the treatment of progesterone resistant endometrial cancer (EC), and a polysialylated form of erythropoietin for the treatment of anemia in pre-dialysis patients with chronic kidney disease. Xenetic is also working together with Shire plc (formerly Baxalta, Baxter Incorporated and Baxter Healthcare) to develop a novel series of polysialylated blood coagulation factors, including a next generation Factor VIII. This collaboration relies on Xenetic's PolyXen technology to conjugate polysialic acid (“PSA”) to therapeutic blood-clotting factors, with the goal of improving the pharmacokinetic profile and extending the active life of these biologic molecules. Shire is a significant stockholder of the Company, having invested $10 million in the Company during 2014. The agreement is an exclusive research, development and license agreement which grants Shire a worldwide, exclusive, royalty-bearing license to Xenetic's PSA patented and proprietary technology in combination with Shire's proprietary molecules designed for the treatment of blood and bleeding disorders. Under the agreement, Xenetic may receive regulatory and sales target payments for total potential milestone receipts of up to $100 million plus royalties on sales. Additionally, Xenetic has previously received strategic investments from OPKO Health (OPK), Serum Institute of India Limited and Pharmsynthez. Xenetic is also developing a broad pipeline of clinical candidates for next generation biologics and novel oncology therapeutics in a number of orphan disease indications.

New Sports Companies Added:
Netshoes (Cayman) Limited (NYSE: NETS) is the leading sports and lifestyle online retailer in Latin America and one of the largest online retailers in the region, with operations in Brazil, Argentina, and Mexico. Through the websites Netshoes and Zattini, as well as through partner-branded store sites it manages, Netshoes offers customers a wide selection of products and services for sports, fashion and beauty. Netshoes recently started to provide B2B operations to partner suppliers, and launched its online third-party marketplace across all of its sites.

Sport Endurance, Inc. (OTCQB:SENZ) develops, markets, and distributes nutritional supplement products throughout the United States. We believe improved health contributes to and promotes a higher quality of life. It’s our goal to improve health by providing quality and effective nutritional supplements. Our primary focus is on three areas of health that most directly impact the lives of most active adults – Total Wellness, Performance, and Recovery.

New Automotive Companies Added:
Xpel Technologies (TSX: DAP-U.V) is the leading supplier of automotive paint, headlamp and window protection films with over 70,000 vehicle-specific applications and a worldwide network of trained installers. Using XPEL’s propriety software and patented materials, our professional design team develops products that deliver the ultimate in vehicle protection, meeting the demands of a broad range of makes and models. XPEL is the developer of the Design Access Program software, and manufacturer of XPEL™ Automotive Paint and Headlamp Protection Products. XPEL has forged the cutting-edge of automotive protection technology, and leads the industry in quality, technical support and customer service.


Investorideas.com global stock directories are part of the membership program on the site, accessed either by login and password or available in PDF format.  The directories include stocks trading on the TSX, OTC, NASDAQ, NYSE and other recognized global stock exchanges, giving retail investors a wide variety of stocks to review. http://www.investorideas.com/membership/

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

About Investorideas.com - News that Inspires Big Ideas
Investorideas.com is a meeting place for global investors, featuring news, stock directories, video, podcasts, company profiles, interviews and more in leading sectors.

Sectors we cover include tech, bitcoin and blockchain, biotech, mining, energy, renewable energy, water stocks, marijuana and hemp stocks, food and beverage (including organic and LOHAS, wine), defense and security (including biometrics), Latin America, sports, entertainment, luxury brands and gaming.

The Investorideas.com content portfolio goes beyond the www.investorideas.com site to include 12 blogs on Blogger.com, 7 Artificial Intelligence (AI) websites on the Grid and the Waternewswire.com, all featuring Investorideas.com news and content.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Investor Ideas Directories for global investors:
From water stocks to gold and mining stocks, renewable energy, nanotech, defense, technology, biotech and more – use our stock directories and access them online 24/7 with login as a member to find your next big idea!

Services for Publicly traded companies: http://www.investorideas.com/Investors/Services.asp

Investorideas.com CSE service provider directory listing: http://thecse.com/en/services/services-for-listed-companies


Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution,social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.  Global investors must adhere to regulations of each country.

Contact Investorideas.com
800-665-0411














Breaking News: Cellular Biomedicine Group ( NASDAQ: $CBMG) and #GE Healthcare Life Sciences China Announce Strategic Partnership to Establish Joint Technology Laboratory to Develop Control Processes for the Manufacture of CAR-T and Stem Cell Therapies

Breaking News: Cellular Biomedicine Group ( NASDAQ:  $CBMG) and  #GE Healthcare Life Sciences China Announce Strategic Partnership to Establish Joint Technology Laboratory to Develop Control Processes for the Manufacture of CAR-T and Stem Cell Therapies



SHANGHAI, China and CUPERTINO, Calif., April 10, 2017-- Cellular Biomedicine Group Inc. (NASDAQ: CBMG) (CBMG or the Company), a leading clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases and GE Healthcare Life Sciences China, today announced that they have established a strategic research collaboration to co-develop certain high-quality industrial control processes in Chimeric Antigen Receptor T-cell (CAR-T) and stem cell manufacturing.  In connection with the collaboration, a joint laboratory within CBMG`s new Shanghai Zhangjiang GMP-facility will be established and dedicated to the joint research and development of a functionally integrated and automated immunotherapy cell preparation system.

CBMG and GE Healthcare Life Sciences China plan to develop state-of-the-art automated CAR-T and stem cell manufacturing capabilities that build upon the accreditation of CBMG`s GMP facilities in Shanghai, Wuxi and Beijing.  The co-development activity will aim to standardize the delivery of cell manufacturing to potentially improve throughput, alleviate cost burdens and to minimize variability in cell production, which may increase the availability of engineered cells upon commercialization.

This partnership combines CBMG`s scientific expertise in the manufacturing of CAR-T and stem cell production in China and GE Healthcare`s renowned expertise in the design and development of innovative manufacturing technologies for the biopharmaceutical industry.

Recently, CBMG announced that its new Zhangjiang facility, together with an expanded Wuxi, and Beijing GMP-facilities, will have a combined 70,000 square feet for development and production. This will enable CBMG to conduct simultaneous clinical trials for multiple CAR-T and stem cell product candidates. At full production volumes, these facilities could support the treatment of up to 10,000 cancer patients and 10,000 knee osteoarthritis patients per year.

"GE Healthcare`s selection of our facility to serve as their showcase site in China, credits our GMP stature and capabilities. Our team of scientists has spent years refining our manufacturing process to become one of the very few cell therapy companies with fully in-house integrated chemistry, manufacturing, and controls (CMC) processes for clinical grade CAR-T cells, plasmid and viral vectors bank production. We understand that one of the impending barriers to adoption of immuno-oncology and stem cell therapies is the logistics in manufacturing and we look to take an expanded role both domestically and potentially globally.  We are pleased to be in a strategic partnership with GE Healthcare and look forward to showcasing our facilities and the mutual benefit this joint laboratory will bring," commented Tony Liu, Chief Executive Officer, CBMG.

"Cell therapy as an industry continues to refine and evolve in China with vast potential to change the ways various diseases are treated.  GE continues investing in technologies and services aimed at the thriving cell therapy industry with a firm commitment of making these promising therapies accessible through successful industrialization. We are pleased to partner with CBMG, a leader in CAR-T and stem cell development in China and to take advantage of their excellent CMC cell production capabilities. Collaboration with ambitious partners like CBMG who share our vision is necessary for advancing innovation and delivering comprehensive manufacturing solutions for cell and regenerative medicines," said Li Qing, General Manager, GE Healthcare Life Sciences, Greater China.


About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. (CBMG) develops proprietary cell therapies for the treatment of cancer and degenerative diseases. We conduct immuno-oncology and stem cell clinical trials in China using products from our integrated GMP laboratory. Our GMP facilities in China, consisting of twelve independent cell production lines, are designed and managed according to both China and U.S. GMP standards.  CBMG recently commenced two Phase I human clinical trials in China using CAR-T to treat relapsed/refractory CD19+ B-cell Acute Lymphoblastic Leukemia (ALL) and Refractory Diffuse Large B-cell Lymphoma (DLBCL) as well as an ongoing Phase I trial in China for AlloJoinTM (CBMG`s "Off-the-Shelf" Allogeneic Human Adipose-derived Mesenchymal Stem Cell) for the treatment of Knee Osteoarthritis (KOA). CBMG was also recently awarded $2.29 million from the California Institute for Regenerative Medicine (CIRM) to support pre-clinical studies of AlloJoinTM for Knee Osteoarthritis in the United States. To learn more about CBMG, please visit www.cellbiomedgroup.com.

About GE Healthcare
GE Healthcare provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world.  GE (GE) works on things that matter - great people and technologies taking on tough challenges. From medical imaging, software & IT, patient monitoring and diagnostics to drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions, GE Healthcare helps medical professionals deliver great healthcare to their patients. For more information about GE Healthcare, visit our website at www.gehealthcare.com.

Forward-Looking Statements
This press release contains forward-looking statements-including descriptions of plans, strategies, trends, specific activities, investments and other non-historical facts-as defined by the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently uncertain, and actual results could differ materially from those anticipated due to a number of factors, which include risks inherent in doing business, trends affecting the global economy (including the devaluation of the RMB by China in August 2015), and other risks detailed in CBMG`s reports filed with the Securities and Exchange Commission, quarterly reports on form 10-Q, current reports on form 8-K and annual reports on form 10-K. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," "continue" or similar terms or their negations. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.

The photo is also available at Newscom, www.newscom.com, and via AP PhotoExpress.

Contacts:
Sarah Kelly
Director of Corporate Communications, CBMG
+1 408-973-7884

Vivian Chen
Managing Director Investor Relations, Citigate Dewe Rogerson
+1 347 481-3711



BiotechIndustryStocks.com - investing ideas in biotechnology stocks, medical technology and life sciences

Like Biotech Stocks? View our Biotech Stocks Directory    Get News Alerts on Biotech Stocks

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.